Document:

Note

 Exhibit 10.13 
  
 NOTE 
  

	 $50,000,000.00 
	 August 27, 2004 

  
 FOR VALUE RECEIVED, BROOKE CREDIT FUNDING, LLC, a Delaware limited liability company (the “Borrower”), promises to pay to AUTOBAHN
FUNDING COMPANY LLC (the “Lender”) the principal sum of FIFTY MILLION DOLLARS ($50,000,000.00) or, if less, the aggregate unpaid principal amount of the loans (the “Advances”) made by the Lender to the Borrower
pursuant to the Credit Agreement (as defined below) on the dates specified in Article II of the Credit Agreement, and to pay the Interest (as defined in the Credit Agreement) on the unpaid principal amount of this Note on the dates specified in
Article II of the Credit Agreement. 
  
 This Note is issued
pursuant to Section 2.15 of the Credit and Security Agreement dated as of August 27, 2004 (as amended, restated, supplemented, or otherwise modified from time to time, the “Credit Agreement”) among the Borrower, Brooke Corporation,
Brooke Credit Corporation, the Lender and DZ Bank AG Deutsche Zentrale-Genossenschaftsbank, as agent (the “Agent”). Capitalized terms used but not defined in this Note are used with the meanings ascribed to them in the Credit
Agreement. 
  
 Notwithstanding any other provisions contained in
this Note, if at any time the Interest payable by the Borrower under this Note, when combined with any and all other charges provided for in this Note, in the Credit Agreement or in any other document (to the extent such other charges would
constitute interest for the purpose of any applicable law limiting interest that may be charged on this Note), exceeds the highest rate of interest permissible under applicable law (the “Maximum Lawful Rate”), then so long as the
Maximum Lawful Rate would be exceeded the rate of interest under this Note shall be equal to the Maximum Lawful Rate. If at any time thereafter the rate of interest payable under this Note is less than the Maximum Lawful Rate, the Borrower shall
continue to pay interest under this Note at the Maximum Lawful Rate until such time as the total interest paid by the Borrower is equal to the total interest that would have been paid had applicable law not limited the interest rate payable under
this Note. In no event shall the total interest received by the Lender under this Note exceed the amount which the Lender could lawfully have received had the interest due under this Note been calculated since the date of this Note at the Maximum
Lawful Rate. 
  
 Payments of the principal of, premium, if any,
and Interest on this Note shall be made by the Borrower to the holder hereof by wire transfer of immediately available funds in the manner and at the times specified in the Credit Agreement, or in such manner or at such other address as the holder
of this Note shall have specified in writing to the Borrower for such purpose, without the presentation or surrender of this Note or the making of any notation on this Note. 
  
 If any payment under this Note falls due on a day which is not a Business Day, then such due date shall be extended to the
next succeeding Business Day and Interest shall be payable on any principal so extended. 
  

 1 

 The Borrower expressly waives presentment, demand, diligence, protest and all notices of any kind
whatsoever with respect to this Note. 
  
 This Note is secured by
the security interests granted to the Agent pursuant to the Credit Agreement, the holder of this Note is entitled to the benefits of the Credit Agreement and may enforce the agreements of the Borrower contained in the Credit Agreement and exercise
the remedies provided for by, or otherwise available in respect of, the Credit Agreement, all in accordance with the terms of the Credit Agreement. If an Event of Default shall occur and be continuing, the unpaid balance of the principal of this
Note, together with accrued Interest, may be declared and become due and payable in the manner and with the effect provided in the Credit Agreement. 
  
 THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS (WITHOUT APPLICATION OF ITS CONFLICT OF LAWS PROVISIONS) OF THE STATE
OF NEW YORK. 
  

 IN WITNESS WHEREOF, the Borrower has caused this Note to be signed and delivered by its duly authorized
officer as of the date set forth above. 
  

					
	 BROOKE CREDIT FUNDING, LLC

		
	By:	 	 /s/ Michael Lowry

	 	 	 Name:
	 	 Michael Lowry

	 	 	 Title:
	 	 President

  

 Schedule to Note 
  

							
	 Date of
 Advance or
 Repayment

	  	 Principal
 Amount of
 Advance

	  	 Principal
 Amount of
 Repayment

	  	 Outstanding
Principal
 Amount

  

 4Employment Agreement

 EXHIBIT 10.28 
  
 August 19, 2004 
  
 Martin E. Schmieg 
 640 W. Carpenter Lane 
 Philadelphia, PA 19119 
  
 Dear Martin: 
  
 This letter
shall serve to set forth the terms of employment offered to you by Sirna Therapeutics, Inc. (the “Company”) and acknowledge your acceptance of the employment on such terms as detailed below. This letter (agreement) shall become effective
upon the mutually agreed upon start date of your employment with the Company (the “Effective Time”). 
  
 Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them on Attachment A hereto, which is incorporated
herein. 
  
 1. Positions and Scope of Employment. Upon the
Effective Time, you shall serve as Senior Vice President and Chief Financial Officer of the Company. You shall render such business and professional services in the performance of your duties, consistent with your position within the Company,
consistent with the Bylaws of the Company and as shall reasonably be assigned to you by the Company’s President and Chief Executive Officer and/or the Board of Directors (the “Board”), and you shall report directly to the President
and Chief Executive Officer. You shall perform your duties faithfully and to the best of your ability and shall devote your full business efforts and time to the Company. 
  
 2. Compensation. 
  
 (a) Base Salary; Annual Reviews. During the period beginning as of the Effective Time and ending on December 31, 2004, the Company shall pay to you
as compensation for your services a base salary at the annualized rate of $250,000 (the “Base Salary”). Thereafter, your Base Salary shall be subject to annual performance review by the President and Chief Executive Officer. Your Base
Salary shall be paid in accordance with the Company’s normal payroll practices. 
  
 (b) Bonus. In each calendar year of your employment with the Company you shall be eligible to earn a bonus. The annual bonus shall be based upon attainment of goals which shall be mutually agreed upon by you
and the President and Chief Executive Officer. The amount of the annual bonus which you shall be eligible to earn shall be equal to twenty five percent (25%) of your then current annual Base Salary in the event: (a) you achieve such goals, and (b)
the Company achieves its corporate goals. This amount shall be pro rated for the 2004 calendar year based upon the portion thereof during which you were employed by the Company. Your bonus shall be reasonably increased or decreased based on the
overachievement or underachievement of such goals. Such bonus shall be payable in a cash lump sum within sixty (60) days after the end of the calendar year with respect to which the bonus is payable. 
  
 Sirna Employment Agreement-Martin 

 (c) Options. The Company shall grant to you stock options to purchase 250,000 shares of the
Company’s common stock. The stock option grant shall be governed by the terms of Company’s Stock Option Plan and the exercise price for the stock option will be the NASDAQ market closing price per share on the start date of employment with
the Company. Such options shall be exercisable for a period of ten (10) years at an exercise price equal to the Fair Market Value (as defined in the Company’s stock option plan) on the date of the stock option grant. Twenty five percent (25%)
of the stock options granted herein shall vest on an annual basis during the first year of your employment with the Company and the remaining seventy five percent (75%) of the stock options shall vest thereafter on a monthly basis over the
subsequent (3) years so as to be fully vested at the end of a period of four (4) years after the Effective Time. Each stock option grant shall be in the form of incentive stock options in the maximum amount permitted by applicable law. You will also
be considered for additional grants of stock options in connection with each annual review by the Board. 
  
 (d) Employee Benefits. During your employment with the Company, you shall be entitled to participate in the employee benefit plans currently and
hereafter maintained by the Company, which shall include, without limitation, the following: 
  
 (i) group PPO medical and dental insurance plans (the coverage under which shall include your dependents and contain no restrictions relative to pre-existing conditions and will be effective on the first day of the
first month after Effective Time); 
  
 (ii) short-term disability
insurance and long-term disability insurance (which coverage shall contain no restrictions relative to pre-existing conditions); 
  
 (iii) term life insurance in the guaranteed amount of $425,000 with the option of completing an evidence of insurability for an additional $75,000, and
with your having the right to designate the beneficiary(ies) thereof; 
  
 (iv) participation in the Company’s 401(k) plan, your contributions to which may be matched by the Company with contributions of shares of its common stock if approved by the Board; provided that any such matching contributions shall
vest over three (3) years of service (you can enroll on the first available date allowed under the plan following the Effective Time); 
  
 (v) participation in the Company’s Flexible Spending Account; and 
  
 (vi) participation in the Company’s Stock Purchase Plan, allowing purchase of shares of the Company’s common
stock at fifteen percent (15%) below the market price (you can enroll on the first available date allowed under the Plan following the Effective Time). 
  
 The Company reserves the right to revise, add or rescind any benefits at any time for its employees generally; provided that any such permitted revision,
addition or rescission of benefits by the Company shall be without prejudice to your rights provided in Section 4(d) hereof. 
  
 Sirna Employment Agreement-Martin 
  

 2 

 (e) Vacation Days; Sick Days; Holidays. You shall be entitled to paid vacation, sick days and
holidays in accordance with the Company’s policies as in effect from time to time, as well as all applicable state and federal laws. 
  
 (f) Expenses. The Company shall reimburse you for reasonable travel, entertainment or other expenses incurred by you in the furtherance of or in
connection with the performance of your duties on behalf of the Company and/or for Company approved personal professional development in accordance with the Company’s expense reimbursement policy as in effect from time to time. 
  
 3. Termination. 
  
 (a) At-Will Employment. You and the Company agree that your
employment with the Company shall be “at-will” employment, that you are free to resign and, subject to the provisions hereof, the Company is free to terminate your employment at any time for any reason or no reason. 
  
 (b) Voluntary Termination; Termination for Cause. In the event that
your employment with the Company is terminated voluntarily by you or for Cause by the Company, then (i) all options which have vested shall continue to be exercisable in accordance with the terms of the Company’s stock option plan and
applicable legal requirements; (ii) all payments of Base Salary accrued but unpaid on the date of termination, as well as all expenses incurred to the date of termination, shall be due and payable to within the required timeframe allowed by law and
all further compensation by the Company to you hereunder shall terminate as of the date of termination; and (iii) you shall be entitled to continue medical and dental insurance coverage for yourself and your dependents, at your expense, at the same
level of coverage as was provided to the you under the Company’s insurance plan immediately prior to the termination (“Health Care Coverage”) by electing COBRA continuation coverage (“COBRA”) in accordance with applicable
law. 
  
 (c) Termination upon Death or Disability. In the
event that your employment with the Company is terminated as a result of your death or permanent disability then (i) all options which have vested shall continue to be exercisable in accordance with the terms of the Company’s stock option plan
and applicable legal requirements; (ii) the Company shall pay to you, your estate or your designated trust, as applicable, all payments of Base Salary and bonuses accrued but unpaid on the date of termination, as well as expenses incurred to the
date of termination, immediately upon the date of termination and all further compensation by the Company to you hereunder shall terminate as of the date of termination; and (iii) you shall be entitled to continue medical and dental insurance
coverage for yourself and your dependents, at your expense, at the same level of coverage as was provided to you under the Company’s Health Care Coverage by electing COBRA in accordance with applicable law. For purposes hereof, the term
“permanent disability” shall mean your inability to perform your duties as they exist at the time disability commences on account of illness, accident or other physical or mental incapacity which shall continue for a consecutive period of
ninety (90) days or an aggregate of one hundred twenty (120) days in any consecutive twelve-month period. 
  
 Sirna Employment Agreement-Martin 
  

 3 

 (d) Termination without Cause. In the event that your employment with the Company is terminated by
the Company without Cause, then (i) all options which have vested shall continue to be exercisable in accordance with the terms of the Company’s stock option plan and applicable legal requirements; (ii) all payments of Base Salary and bonuses
accrued in accordance with Company’s policy, but unpaid on the date of termination, as well as all expenses incurred to the date of termination, shall be due and payable to you immediately; (iii) subject to the provisions of Section 4 hereof,
your unvested options shall continue to vest, on a monthly basis, during the nine (9) month severance period described in Section 3(d)(iv) below, but such continuing vesting of your unvested options shall cease upon your obtaining new employment
during the applicable severance period; (iv) the Company shall pay to you a severance payment, in monthly installments, equal to your Base Salary for a period of nine (9) months; provided, however, that in the event you are terminated as a result of
a Change of Control (other than for Cause), the amount of such severance payment shall be twelve (12) months’ severance; provided, further, that in the event you obtain other employment during the applicable nine (9) or twelve (12) month
severance period, your severance payments thereafter shall be reduced on a prospective basis (not to less than 0) in the amount of cash compensation received by you during the remainder of such applicable severance period; and (v) the Company shall
be responsible for all costs relating to maintaining your Health Care Coverage for you and your dependents under COBRA during the designated severance period. You shall be entitled to continue medical and dental insurance coverage for yourself and
your dependents for the remaining period, at your expense in accordance with applicable law. However, such Health Care Coverage shall terminate upon your obtaining alternative Health Care Coverage (after completing any waiting periods for such
coverage to become effective). 
  
 4. Change of Control.
Notwithstanding anything to the contrary contained herein, in the event of a Change of Control of the Company if your employment is terminated by the Company within one (1) year after the Change of Control (other than for cause), then: (i) the
greater of (a) fifty percent (50%) of your unvested options shall vest immediately, or (b) your unvested options shall continue to vest, on a monthly basis, during the twelve (12) month severance period described in Section 3(d)(iv) above; and (ii)
the Company shall pay to you a severance payment in accordance with the provisions of Section 3(d) above. 
  
 5. Non-Disclosure and Non-Competition Agreement and Invention Assignment Agreement. You will enter into the Company’s standard Non-Disclosure
and Non-Competition Agreement and Invention Assignment Agreement upon commencing employment hereunder, in the forms of Attachment B and Attachment C hereto. 
  
 6. Directors’ and Officers’ Liability Policy. You will be covered under the Company’s directors’
and officers’ liability insurance policy, which shall provide coverage in an amount and upon terms customary to similarly situated companies. The Company shall maintain a policy throughout the duration of your employment. 
  
 7. Relocation Expenses associated with this Agreement. Terms for
reimbursement of expenses associated with your relocation from Philadelphia, Pennsylvania to Colorado, shall be in accordance with the terms set forth in enclosed 
  
 Sirna Employment Agreement-Martin 
  

 4 

 Attachment D. If employment is terminated voluntarily or for cause within one (1) year of payment/reimbursement by
Company then 100% of relocation expenses are to be promptly (but in no event later than 30 days following the termination) repaid to Company. 
  
 8. Indemnification. The Company agrees that if you are made a party or are threatened to be made a party to any action, suit or proceeding, whether
civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that you are or were a director, officer, employee or agent of the Company or any subsidiary or affiliate of the Company, whether or not the basis of
such Proceeding is alleged action in an official capacity as a director, officer, employee or agent, you shall be indemnified and held harmless by the Company to the fullest extent authorized by Delaware law, as the same exists or may hereafter
amended, against all damages, losses, judgments, liabilities, fines, penalties, excise taxes, settlements and costs, including reasonable attorneys’ fees, accountants’ fees and disbursement, incurred or suffered by you in connection
therewith (including the advancement of your defense costs and expenses as and when incurred) and such indemnification shall continue as to you even if you have ceased to be an officer, director or agent and are no longer employed by the Company and
shall inure to the benefit of your heirs, executors and administrators. 
  
 9. Assignment. This Agreement shall be binding upon and inure to the benefit of (a) your heirs, executors and legal representatives upon your death and (b) any successor or assignee of the Company. Any successor of the Company shall
be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or
otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. 
  
 10. Notices. All notices, requests, demands and other communications provided hereunder shall be in writing and shall be deemed given (i) on the
date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight service, or (iii) four (4) days after being mailed by registered or certified mail, return receipt requested, prepaid and
addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing: 
  
 If to the Company: 
  
 SIRNA THERAPEUTICS, INC. 
 2950 Wilderness Place 
 Boulder, Colorado 80301 
 Attn: President & CEO 
 Copy to: V. P. Legal Affairs 
  
 If to you: 
  
 at the last residential address known by the Company. 
  
 11. Severability. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision.

  
 Sirna Employment Agreement-Martin 
  

 5 

 12. Integration. Upon the Effective Time, this Agreement, together with the Non-Disclosure
Agreement, Invention Assignment Agreement and the Non-Competition/Non-Solicitation Agreement, represents the entire agreement and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous
agreements whether written or oral. No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives of the parties hereto. 
  
 13. Governing Law. This Agreement shall be governed by and interpreted
in accordance with the laws of the State of Colorado, without reference to principles of conflict of laws. You and the Company each hereby submits, exclusive jurisdiction of the courts located in the State of Colorado and any courts of appeal
therefrom, and waives any objection (on the grounds of lack of jurisdiction, or forum non coveniens or otherwise) to the exercise of such jurisdiction by any such courts. 
  
 14. Effective Time. This Agreement shall become effective at the Effective Time. 
  
 Please sign this Agreement and return one signed original copy to me,
acknowledging your agreement with and acceptance of these terms of employment. 
  
  

			
	Sincerely,
	
	SIRNA THERAPEUTICS, INC.
		
	By:	 	 /s/ Howard W. Robin

	Name:	 	Howard W. Robin
	Title:	 	President & CEO

  
 Agreed and accepted: 

 
 /s/ Martin E. Schmieg 

 Martin E. Schmeig 
 Dated: August, 2004 
  
 Sirna Employment Agreement-Martin 
  

 6 

 Attachment A 
  
 DEFINITIONS 
  
 Cause. “Cause” is defined as (i) conviction of a felony crime involving moral turpitude, (ii) an intentional action or intentional
failure to act which was performed in bad faith and to the material detriment of the Company, (iii) continued intentional refusal or intentional failure to act in accordance with any lawful and proper direction or order of the Board, (iv) willful
and habitual neglect of the duties of employment, or (v) breach of the Non-Disclosure Agreement, contemplated hereunder; provided, however, that with respect to the events of “cause” described under clauses (ii) through (v) above, the
Company shall have first provided to you written notice describing the nature of the event and, thereafter, provided a reasonable opportunity to cure such event, which reasonable opportunity shall in no event be less than thirty (30) days following
receipt of such notice. 
  
 Change of Control. “Change
of Control” of the Company is defined as: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “beneficial owner” (as defined in Rule 13d-3 under
said Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or (ii) the consummation of a merger or
consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such
surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company; or (iii) the consummation of the sale or disposition by the Company of all or
substantially all the Company’s assets; or (iv) when the individuals who on the date hereof constitute the Board and any new director (other than a director designated by a person or entity who has entered into an agreement to effect a
transaction described in clause (i), (ii) or (iii) above), whose nomination and/or election to the Board was approved by a vote of at least a majority of the directors still in office who either were directors on the date hereof or whose election or
nomination for election was previously approved, cease for any reason constitute a majority of the Board. 
  
 Sirna Employment Agreement-Martin 
  

 7 

 Attachment B 
  
 Attachment B 
  
 NON-DISCLOSURE AND NON-COMPETITION AGREEMENT  
  
 IN CONSIDERATION of my employment and continued employment by Sirna Therapeutics, Inc. (the “Company”), I hereby agree as follows: 

 

	1.	During the continuance of my employment with the Company and subsequent thereto, I will not, directly or indirectly, disclose or reveal to any person, firm, or corporation, or use
for my benefit or for the benefit of any person, firm, or corporation, any knowledge or information which I may acquire concerning the Company’s business or products, including, without limitation, technology, manufacturing processes, formulas,
formulations, processes, discoveries, patents, patent applications, research, product development, marketing plans, research and development plans, systems, names, types, quantities or sources of supply of materials used or sold by the Company,
pricing information, the identities of former or existing customers of the Company and other trade or business secrets or other confidential information of the Company, which shall also include any confidential information of any other party
revealed to me during my employment by the Company. Upon termination of my employment with the Company, I will forthwith return to the Company all documents, lists, books, records, computer tapes, and disks relating to the foregoing and the business
or customers of the Company and all other property belonging to it. I further agree that the Company’s information processing equipment, software and services are not to be used for personal gain or purposes. 

  

	2.	I further agree that during the continuance of my employment with the Company and for a period of one (1) year after the termination of my employment with the Company for any reason
(with or without cause) (the “Non-Competition Period”): (i) I will not, anywhere in the United States, engage, without the express prior written consent of the Company, in any business or activity in direct competition with Company in the
then current Field of Interest (as defined below), whether as an employee, consultant, partner, principal, agent, representative, equity holder or in any other individual, corporate or representative capacity (without limitation by specific
enumeration of the foregoing), or render any services or provide any advice to any person, company or other entity (each, a “Person”) in direct competition with the Company in the then current Field of Interest (a “Competing
Business”); (ii) I will not, anywhere in Colorado, engage, without the express prior written consent of the Company, in any business or activity in direct competition with the Company in the then current Field of Interest, whether as an
employee, consultant, partner, principal, agent, representative, equity holder or in any other individual, corporate or representative capacity (without limitation by specific enumeration of the foregoing), or render any services or provide any
advice to any Competing Business; and (iii) I will not, in any of the counties in the State of Colorado, engage, without the express prior written consent of the 

  
 Sirna Employment Agreement-Martin 
  

 8 

 Company, in any business or activity in direct competition with the Company in the then current Field of
Interest, whether as an employee, consultant, partner, principal, agent, representative, equity holder or in any other individual, corporate or representative capacity (without limitation by specific enumeration of the foregoing), or render any
services or provide any advice to any Competing Business. 
  

	3.	I acknowledge that the Company proposes that its principal business activities shall relate to the research, development, manufacture, license, sale and distribution of therapeutic
products using small interfering nucleic acid (siNA), including without limitation, small interfering RNA (siRNA), technology (hereinafter, “siNA Technology”). During the Non-Competition Period, the Company may, in addition to or in
substitution for siNA Technology, have additional platform technologies as its principal business activity or activities, including without limitation programs in therapeutic areas where the Company has advanced a product into pre-clinical
toxicology or later stages of development (the “Field of Interest”). For example, the current Field of Interest would include without limitation the viruses HBV and HCV and the therapeutic gene target VEGF-Receptor R-1, which are within
the scope of the Company’s current principal business activities, but other therapeutic areas, such as anti-viral therapeutic products and specific cancer therapeutics, would exceed the scope of activities covered by the current Field of
Interest. 

  

	4.	Notwithstanding anything to the contrary contained in this Agreement, upon the termination of my employment with the Company for any reason (with our without cause), it is
understood and agreed that I may thereafter engage, without the consent of the Company, in any business or activity, whether as an employee, consultant, partner, principal, agent, representative, equity holder or in any other individual, corporate
or representative capacity (without limitation by specific enumeration of the foregoing) for any Person that is engaged in the then current Field of Interest at the time of termination of my employment with the Company, so long as (i) the principal
business activity of such Person is not in such Field of Interest and (ii) I do not personally engage or provide counsel, advice or direction in any activities that are within such Field of Interest for such Person. 

  

	5.	Notwithstanding the foregoing, I may own, directly or indirectly, up to one percent (1%) of any class of “publicly traded securities” of any Person which owns or operates
a business that is a Competing Business. For the purposes of this Section 5, “publicly traded securities” shall mean securities that are traded on a national securities exchange or listed on the Nasdaq National Market.

  

	6.	I further agree that, during the Non-Competition Period, I will not for any reason intentionally or knowingly or willfully (i) solicit or divert any business, clients, customers, or
partners made known by me during his employment with the Company away from the Company, (ii) induce customers, clients, partners, suppliers, agents or other Persons under contract or otherwise associated or doing business with the Company who are
made known by me during his employment 

  
 Sirna Employment
Agreement-Martin 
  

 9 

 with the Company to reduce or alter any such association or business with the Company, and/or (iii)
solicit any Person in the employment of the Company to (A) terminate such employment, and/or (B) accept employment, or enter into any consulting arrangement, with any Person other than the Company. 
  

	7.	To my knowledge, this Agreement is a legal, valid and binding obligation, enforceable against me in accordance with its terms to the fullest extent permitted under applicable
federal, state or local law. 

  

	8.	For the purposes of this Agreement, the term “Company” shall include any related or affiliated companies of Sirna Therapeutics, to the extent such related or affiliated
companies engage in activities related to the Field of Interest. 

  

	9.	In the event I breach, or threaten, or attempt to breach, any of the covenants set forth in this Agreement, I, recognizing that immediate and irreparable injury will be caused the
Company, agree that in addition to any other rights and remedies of the Company, each said covenant may be enforced by an action to obtain an injunction or restraining order, which may be granted immediately and without prior notice upon
commencement of such action. 

  

	10.	To the extent any provision of this Agreement shall be determined to be unlawful or otherwise unenforceable, in whole or in part, such determination shall not affect the validity of
the remainder of this Agreement, and this Agreement shall be reformed to the extent necessary to carry out its provisions to the greatest extent possible. In the absence of such reformation, such part of such provision shall be considered deleted
from this Agreement and the remainder of such provision and of this Agreement shall be unaffected and shall continue in full force and effect. In furtherance and not in limitation of the foregoing, should the duration or geographical extent of, or
business activities covered by any provision of this Agreement be in excess of that which is valid and enforceable under applicable law, then such provision shall be construed to cover only that duration, extent or activities which may validly and
enforceably be covered. To the extent any provision of this Agreement shall be declared invalid or unenforceable for any reason by any governmental entity in any jurisdiction, this Agreement (or provision thereof) shall remain valid and enforceable
in each other jurisdiction where it applies. I acknowledge the uncertainty of the law in this respect and expressly stipulate that this Agreement shall be given the construction which renders its provisions valid and enforceable to the maximum
extent (not exceeding its express terms) possible under applicable law. 

  

	11.	This Agreement will be governed by the law of Colorado. 

  

			
	Date: August 19, 2005	  	 /s/ Martin E. Schmieg

	 	  	Signature
		
	 	  	 Martin E. Schmieg

	 	  	Name (Print or Type)

  
 Sirna Employment Agreement-Martin

  

 10 

 Attachment C 
  
 ASSIGNMENT OF INVENTIONS 
  
 Sirna Employment Agreement-Martin 
  
  

 11 

 Attachment D 
  
 RELOCATION TERMS 
  
 RELOCATION PACKAGE: COMPANY WILL PROVIDE THE FOLLOWING RELOCATION ASSISTANCE. 
  

					
	Temporary travel Between Philadelphia, PA and Denver, CO	  	 •
	  	 Reimbursement for temporary travel between Denver and Philadelphia for up to 9 months at the rate of $1,200 per month
  

	  	 •
	  	 Any unused amount in a given month may be applied towards reimbursement of temporary travel expenses during the remainder of the 9-month
period
  

			
	Temporary Living	  	•	  	 Reimbursement for temporary living accommodations(housing, utilities) for up to 9 months
  

	  	•	  	 Up to $2,000/month temporary living maximum
  

	  	•	  	 Up to $250.00/month for meals.
  

	  	•	  	 If needed, a rental car for up to 9 months.
  

			
	Moving of Household Goods	  	 •
	  	 The Cost of packing, crating, insuring, movement and unpacking of normal household goods. No weight limit.
  

	  	•	  	 The cost of moving up to 3 automobiles
  
  

	  	•	  	 Excludes items not normally moved by the relocation service (e.g., RV’s, boats, perishables, firewood, house plants, pets, hobby equipment,
articles of extraordinary value (jewelry, precious stones, etc.)
  

			
	Family Travel To New Location	  	•	  	 By air: One-way coach
  

	  	•	  	By auto: at $0.32/mile
			
	Sale of Primary Residence in Pennsylvania	  	•	  	Reasonable and customary fees associated with the sale of your primary residence in Pennsylvania will be reimbursed, such as commission (not to exceed 6%), inspections, survey, appraisals, title
insurance, transfer fees, attorney’s fees, and other normal closing costs required by seller.
			
	Purchase of Primary Residence in Colorado	  	 •
	  	 Reasonable and customary fees associated with the purchase of a primary residence will be reimbursed such as costs of inspections, survey,
appraisals, title insurance, transfer fees, attorney’s fees, and other normal closing costs required by purchaser.
  

	  	 •
	  	Company shall pay up to 3 points (loan origination fees) associated with the purchase of your primary residence in Colorado

  
 Sirna Employment Agreement-Martin

  

 12 

					
	Tax Reimbursement	  	•	  	Any taxable expenses associated with your relocation that are non-deductible will be grossed up by Company.
			
	Reimbursement Documentation	  	•	  	All reimbursements herein shall be based on submission of appropriate documentation.
			
	Voluntary Separation or Separation for Cause	  	•	  	Should you voluntarily separate from the Company or if you are terminated for cause, within one (1) year of the completion date of the move/relocation then all costs incurred by Company in
connection with the move/relocation are to be fully and promptly reimbursed by you.

  
 Printed Name: Martin E. Schmeig

  

			
	Signed:	 	 /s/ Martin E. Schmeig

  
 Date: August 19, 2004 
  
 Sirna Employment Agreement-Martin 
  

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]